Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel

Cancer Treatment Reviews

Volumn 34, Issue 3, 2008, Pages 223-230

  Liu, Minetta C ^a   Demetri, George D ^b   Berry, Donald A ^c   Norton, Larry ^d   Broadwater, Gloria ^e   Robert, Nicholas J ^f   Duggan, David ^g   Hayes, Daniel F ^h   Henderson, I Craig ⁱ   Lyss, Alan ^j   Hopkins, Judith ^k   Kaufman, Peter A ^l   Marcom, P Kelly ^e   Younger, Jerry ^m   Lin, Nancy ^b   Tkaczuk, Katherine ⁿ   Winer, Eric P ^b   Hudis, Clifford A ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f INOVA FAIRFAX HOSPITAL   (United States)

^g State University New York College of Environmental Science and Forestry   (United States)

^h UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MISSOURI BAPTIST MEDICAL CENTER   (United States)

^k Memorial Hospital   (United States)

^l DARTMOUTH COLLEGE   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

more..

Author keywords

Adjuvant chemotherapy; Breast cancer; Dose escalation; Dose intensification; Doxorubicin cyclophosphamide; Filgrastim; Node positive; Paclitaxel

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; HORMONE RECEPTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; ESOPHAGITIS; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; INFORMATION PROCESSING; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PERICARDIAL DISEASE; PILOT STUDY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY DYSFUNCTION; STOMATITIS; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS;

EID: 43049126834     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.11.004     Document Type: Review

References (18)

1. Frei III E., and Canellos G.P. Dose: a critical factor in cancer chemotherapy. Am J Med 69 4 (1980) 585-594
2. Henderson I.C., Hayes D.F., and Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6 9 (1988) 1501-1515
3. Hryniuk W., and Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2 11 (1984) 1281-1288
4. Budman D.R., Berry D.A., Cirrincione C.T., Henderson I.C., Wood W.C., Weiss R.B., et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90 16 (1998) 1205-1211
5. Wood W.C., Budman D.R., Korzun A.H., Cooper M.R., Younger J., Hart R.D., et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330 18 (1994) 1253-1259
6. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83 24 (1991) 1797-1805
7. Seidman A.D., Norton L., Reichman B.S., Crown J.P., Yao T.J., Heelan R., et al. Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 20 4 Suppl 3 (1993) 40-45
8. Jones S.E., Erban J., Overmoyer B., Budd G.T., Hutchins L., Lower E., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 24 (2005) 5542-5551
9. Nabholtz J.M., Senn H.J., Bezwoda W.R., Melnychuk D., Deschenes L., Douma J., et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17 5 (1999) 1413-1424
10. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352 (9132):930-42.
11. Fisher B., Brown A.M., Dimitrov N.V., Poisson R., Redmond C., Margolese R.G., et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8 9 (1990) 1483-1496
12. Fisher B., Rockette H., Fisher E.R., Wickerham D.L., Redmond C., and Brown A. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol 3 12 (1985) 1640-1658
13. Fisher B., Anderson S., Wickerham D.L., DeCillis A., Dimitrov N., Mamounas E., et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15 5 (1997) 1858-1869
14. Fisher B., Anderson S., DeCillis A., Dimitrov N., Atkins J.N., Fehrenbacher L., et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17 11 (1999) 3374-3388
15. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 6 (2003) 976-983
16. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 8 (2003) 1431-1439
17. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
18. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684